These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37835485)

  • 21. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.
    Ahmed O; Yu Q; Patel M; Hwang G; Pillai A; Liao CY; Fung J; Baker T
    J Vasc Interv Radiol; 2023 Apr; 34(4):702-709. PubMed ID: 36521794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study.
    Mosconi C; Gramenzi A; Ascanio S; Cappelli A; Renzulli M; Pettinato C; Brandi G; Monari F; Cucchetti A; Trevisani F; Golfieri R
    Br J Cancer; 2016 Jul; 115(3):297-302. PubMed ID: 27336601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma.
    Zhen Y; Liu B; Chang Z; Ren H; Liu Z; Zheng J
    Onco Targets Ther; 2019; 12():4489-4498. PubMed ID: 31239717
    [No Abstract]   [Full Text] [Related]  

  • 24. Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization.
    Köhler M; Harders F; Lohöfer F; Paprottka PM; Schaarschmidt BM; Theysohn J; Herrmann K; Heindel W; Schmidt HH; Pascher A; Stegger L; Rahbar K; Wildgruber M
    J Clin Med; 2019 Dec; 9(1):. PubMed ID: 31881761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrahepatic cholangiocarcinoma: a dose threshold evaluation in those undergoing transarterial radioembolization.
    Young S; Torkian P; Flanagan S; D'Souza D; Sanghvi T; Golzarian J
    J Gastrointest Oncol; 2023 Oct; 14(5):2202-2211. PubMed ID: 37969824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Boosted-Dose Yttrium-90 Radiation Segmentectomy or Lobectomy for Hepatocellular Carcinoma Refractory to Prior Transarterial Embolization or Chemoembolization: A Single Institution Retrospective Case Series.
    Srinivas S; Rose SC; Al Jammal O; Hsieh LJ; Rockwell HD; Duncan DP; Minocha J; Berman ZT
    Cardiovasc Intervent Radiol; 2023 Apr; 46(4):460-469. PubMed ID: 36854903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience.
    Pellegrinelli J; Chevallier O; Manfredi S; Dygai-Cochet I; Tabouret-Viaud C; Nodari G; Ghiringhelli F; Riedinger JM; Popoff R; Vrigneaud JM; Cochet A; Aho S; Latournerie M; Loffroy R
    Diagnostics (Basel); 2021 Jan; 11(1):. PubMed ID: 33466706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereotactic body radiation therapy is associated with improved overall survival compared to chemoradiation or radioembolization in the treatment of unresectable intrahepatic cholangiocarcinoma.
    Sebastian NT; Tan Y; Miller ED; Williams TM; Alexandra Diaz D
    Clin Transl Radiat Oncol; 2019 Nov; 19():66-71. PubMed ID: 31517072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of results after 112 radioembolizations with
    Casáns-Tormo I; Guijarro-Rosaleny J; Lluch-García P; Rodríguez-Parra H; Roselló-Keränen S; Asensio-Valero L
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(4):255-264. PubMed ID: 37269983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection.
    She WH; Cheung TT; Yau TC; Chan AC; Chok KS; Chu FS; Liu RK; Poon RT; Chan SC; Fan ST; Lo CM
    Hepatobiliary Surg Nutr; 2014 Aug; 3(4):185-93. PubMed ID: 25202695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
    Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of Holmium-166 selective internal radiotherapy of primary and secondary liver cancer confirmed by real-world data.
    Schulze-Zachau V; Verset G; De Bondt P; De Keukeleire K; Gühne F; Heuschkel M; Hoffmann RT; Bozzi E; Sciuto R; Lam M; Deportós Moreno J; Debrus R; Zech CJ
    Front Oncol; 2024; 14():1404621. PubMed ID: 38919523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
    Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
    Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer.
    Puleo L; Agate L; Bargellini I; Boni G; Piaggi P; Traino C; Depalo T; Lorenzoni G; Bianchi F; Volterrani D; Brogioni S; Bottici V; Brunetto MR; Coco B; Molinaro E; Elisei R
    Eur Thyroid J; 2022 Dec; 11(6):. PubMed ID: 36126186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Deterioration of Sarcopenia Post-Transarterial Radioembolization with Holmium-166 Serves as a Predictor for Disease Progression at 3 Months in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study.
    Trobiani C; Ubaldi N; Teodoli L; Tipaldi MA; Cappelli F; Ungania S; Vallati G
    J Pers Med; 2024 May; 14(5):. PubMed ID: 38793093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome and Safety after 103 Radioembolizations with Yttrium-90 Resin Microspheres in 73 Patients with Unresectable Intrahepatic Cholangiocarcinoma-An Evaluation of Predictors.
    Paprottka KJ; Galiè F; Ingrisch M; Geith T; Ilhan H; Todica A; Michl M; Nadjiri J; Paprottka PM
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal and Intestinal Excretion of
    Drescher R; Kühnel C; Seifert P; Gühne F; Freesmeyer M
    AJR Am J Roentgenol; 2020 May; 214(5):1158-1164. PubMed ID: 32130046
    [No Abstract]   [Full Text] [Related]  

  • 38. Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.
    Kim Y; Lee HA; Lee JS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Um SH; Seo YS; Kim SU
    Cancer Invest; 2021 Mar; 39(3):274-283. PubMed ID: 33356630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis.
    Mouli S; Memon K; Baker T; Benson AB; Mulcahy MF; Gupta R; Ryu RK; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2013 Aug; 24(8):1227-34. PubMed ID: 23602420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Radioembolization for Biliary Tract and Primary Liver Cancer.
    Taylor AC; Maddirela D; White SB
    Surg Oncol Clin N Am; 2019 Oct; 28(4):731-743. PubMed ID: 31472916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.